New AusVaxSafety data confirms Abrysvo RSV vaccine is well tolerated during pregnancy; adverse events comparable to other maternal vaccinations

Newly released AusVaxSafety maternal vaccine safety data show Abrysvo RSV vaccination during pregnancy is well tolerated, with early data indicating a similar adverse event profile to other maternal National Immunisation Program vaccines.

AusVaxSafety epidemiologists analysed data from 718 women who received an Abrysvo RSV vaccine during pregnancy between 27 June 2024–31 May 2025 and completed an AusVaxSafety survey allowing participants to report any adverse events they may have experienced following immunisation.

Dr Lucy Deng, Clinical Lead at AusVaxSafety said, ‘This is the first surveillance data published in Australia examining the short-term safety profile of the Abrysvo vaccine outside of a clinical trial setting.’

Key findings show:

• 28% of respondents reported experiencing an adverse event – slightly higher than that seen with maternal pertussis (26%) or influenza (22%) vaccination
• local reaction (23%) was the most commonly reported adverse event, followed by fatigue (18%), muscle ache (myalgia; 12%) and headache (11%)
• 0.7% of respondents reported seeking medical attendance – a similar proportion to that observed for maternal pertussis (0.6%) and influenza (0.7%) vaccination
• impact on routine activities was minimal, with just 5% of respondents reporting missing work, study or routine duties in the days following vaccination.

Compared with receiving Abysvo alone, the rate and type of adverse events in individuals who received Abrysvo concomitantly (i.e. together with another vaccine) remained largely unchanged – aside from local pain, which was higher (28%).

‘If pregnant individuals are due multiple vaccines, the vaccines can be administered together to avoid the need for separate vaccination visits,’ Dr Deng said.

These new safety data have been released as part of the ongoing AusVaxSafety RSV vaccine surveillance program and are updated monthly.

Explore AusVaxSafety’s Abrysvo RSV vaccine safety data